Epidemiology: The prevalent population of hemophilia and von Willebrand disease is predicted to increase between 2015-35.
By Keane Tzong & Niharika Dandamudi, Epidemiologist/ Senior Epidemiologist
5 June 2016
Hemophilia is a rare, inherited X-chromosome linked bleeding disorder. In hemophilia, deficiencies in clotting factors prevent blood from clotting normally. Von Willebrand disease is also an inherited bleeding disorder which results from a deficiency or defect of the von Willebrand factor, a blood clotting protein. Datamonitor Healthcare expects the number of diagnosed prevalent cases of hemophilia A and hemophilia B, and von Willebrand disease across the US, Japan, and five major EU markets to increase during the forecast period (2015–35). Datamonitor Healthcare predicts that there will be limited positive growth in the diagnosed prevalent hemophilia A, hemophilia B and von Willebrand disease populations in the US, France, and UK between 2015–35. There will be negative growth in the diagnosed prevalent population in Japan, Germany, Italy, and Spain. Changes in the diagnosed prevalent patient population of hemophilia A, hemophilia B, and VWD are likely to result from demographic changes in the markets of interest. Meanwhile, the development of improved treatments and subsequent improvements in survival are likely to contribute to an increase in the size of the prevalent patient population.
|Diagnosed prevalent cases of bleeding disorders (hemophilia A, hemophilia B and von Willebrand disease) in the US, Japan, and five major EU markets, in 2015, 2025 and 2035|
|Von Willebrand disease||29,620||30,560||31,340|
|Source: Datamonitor Healthcare; United Nations, 2015; WFH, 2015|